CN114727996A - 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷 - Google Patents

用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷 Download PDF

Info

Publication number
CN114727996A
CN114727996A CN202080058723.0A CN202080058723A CN114727996A CN 114727996 A CN114727996 A CN 114727996A CN 202080058723 A CN202080058723 A CN 202080058723A CN 114727996 A CN114727996 A CN 114727996A
Authority
CN
China
Prior art keywords
azacytidine
days
dose
therapeutic agent
additional therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080058723.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·弗拉蒂尼
C·比奇
S·罗丝
D·R·邓希
D·E·洛佩斯·德·梅内泽斯
K·麦克白
Y·戴
J·江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN114727996A publication Critical patent/CN114727996A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080058723.0A 2019-06-20 2020-06-19 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷 Pending CN114727996A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864413P 2019-06-20 2019-06-20
US62/864,413 2019-06-20
PCT/US2020/038760 WO2020257665A1 (en) 2019-06-20 2020-06-19 Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
CN114727996A true CN114727996A (zh) 2022-07-08

Family

ID=71528047

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080058723.0A Pending CN114727996A (zh) 2019-06-20 2020-06-19 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
CN202080057984.0A Pending CN115066243A (zh) 2019-06-20 2020-06-19 用于治疗白血病或骨髓增生异常综合征的与维奈妥拉、吉特替尼、米哚妥林或其他化合物组合的阿扎胞苷

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080057984.0A Pending CN115066243A (zh) 2019-06-20 2020-06-19 用于治疗白血病或骨髓增生异常综合征的与维奈妥拉、吉特替尼、米哚妥林或其他化合物组合的阿扎胞苷

Country Status (11)

Country Link
US (2) US12447171B2 (https=)
EP (2) EP3986403A1 (https=)
JP (2) JP2022537551A (https=)
KR (2) KR20220050874A (https=)
CN (2) CN114727996A (https=)
AU (2) AU2020296179A1 (https=)
BR (2) BR112021025537A2 (https=)
CA (2) CA3143719A1 (https=)
IL (2) IL289110A (https=)
MX (2) MX2021015993A (https=)
WO (2) WO2020257665A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3597741A1 (en) 2012-04-27 2020-01-22 Duke University Genetic correction of mutated genes
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
EA201891317A3 (ru) 2015-11-30 2019-04-30 Дьюк Юниверсити Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
WO2018017754A1 (en) 2016-07-19 2018-01-25 Duke University Therapeutic applications of cpf1-based genome editing
WO2019144061A1 (en) 2018-01-19 2019-07-25 Duke University Genome engineering with crispr-cas systems in eukaryotes
US20240141341A1 (en) * 2021-03-01 2024-05-02 Duke University Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
WO2022215995A1 (ko) * 2021-04-05 2022-10-13 주식회사 피노바이오 4'-티오-5-아자-2'-디옥시사이티딘 및 베네토클락스의 병용 요법
JP2024517318A (ja) * 2021-05-11 2024-04-19 アッヴィ・インコーポレイテッド アザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン
CN117651556A (zh) * 2021-05-11 2024-03-05 艾伯维公司 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案
US20250312327A1 (en) * 2021-10-14 2025-10-09 Pharos Ibio Co., Ltd Composition for combination therapy, comprising 2,3,5-substituted thiophene compound
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
IL317874A (en) 2022-06-24 2025-02-01 Tune Therapeutics Inc Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782612B1 (en) * 2008-05-15 2023-11-08 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
SI3137169T1 (sl) 2014-05-01 2022-04-29 Celgene Quanticel Research, Inc. Inhibitorji lizin specifične demetilaze-1
EA201790376A1 (ru) 2014-09-05 2017-08-31 Селджен Квонтисел Рисёрч, Инк. Ингибиторы лизин-специфической деметилазы-1
WO2016040238A1 (en) 2014-09-08 2016-03-17 Celgene Corporation Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
PT3362066T (pt) 2015-10-15 2021-11-16 Celgene Corp Terapia de combinação para tratar malignidades
US10695352B2 (en) 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
EP3371152B1 (en) 2015-11-05 2020-12-23 Celgene Quanticel Research, Inc. Compositions comprising an inhibitor of lysine specific demethylase-1 having a pyrimidine ring and its use in the treatment of cancer
CN109462980B (zh) * 2016-03-15 2022-02-08 奥莱松基因组股份有限公司 用于治疗血液恶性肿瘤的lsd1抑制剂的组合
US20200069677A1 (en) * 2016-12-09 2020-03-05 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
EP4201399A3 (en) 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
WO2019012328A1 (en) 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COURTNEY D. DINARDO ETC.: "Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)", BLOOD, vol. 130, pages 639, XP009522609 *
IMAN ABOUDALLE, MD,ETC.: "Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations", BLOOD, vol. 132, pages 2715, XP009522607, DOI: 10.1182/blood-2018-99-117632 *
JORDI ESTEVE, ETC.: "Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort", BLOOD, vol. 132, pages 2736, XP009522606, DOI: 10.1182/blood-2018-99-110976 *
MAHESH SWAMINATHAN，ETC.: "The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial", BLOOD, vol. 130, pages 723, XP009522608 *
POLLYEA, DANIEL A.ETC.: "Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia", NATURE MEDICINE (NEW YORK, NY, UNITED STATES), vol. 24, no. 12, pages 1859 - 1866, XP036653577, DOI: 10.1038/s41591-018-0233-1 *
STRATI, PAOLO,ETC.: "Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome", AMERICAN JOURNAL OF HEMATOLOGY, vol. 90, no. 4, pages 276 - 281 *

Also Published As

Publication number Publication date
US20220249529A1 (en) 2022-08-11
EP3986403A1 (en) 2022-04-27
MX2021015992A (es) 2022-04-06
JP2022537551A (ja) 2022-08-26
CN115066243A (zh) 2022-09-16
IL289110A (en) 2022-02-01
AU2020296179A1 (en) 2022-02-03
WO2020257665A1 (en) 2020-12-24
CA3143719A1 (en) 2020-12-24
EP3986404A1 (en) 2022-04-27
IL289115A (en) 2022-02-01
BR112021025375A2 (pt) 2022-02-01
MX2021015993A (es) 2022-04-06
KR20220024639A (ko) 2022-03-03
CA3143711A1 (en) 2020-12-24
JP2022537384A (ja) 2022-08-25
KR20220050874A (ko) 2022-04-25
US20220249528A1 (en) 2022-08-11
BR112021025537A2 (pt) 2022-03-03
AU2020297596A1 (en) 2022-02-03
WO2020257671A1 (en) 2020-12-24
US12447171B2 (en) 2025-10-21

Similar Documents

Publication Publication Date Title
CN114727996A (zh) 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
Liu et al. A Phase 1 trial of the poly (ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
CN114828844A (zh) 用lsd1抑制剂治疗lsd1相关疾病和病症的方法
CN105873440A (zh) 适用于治疗癌症的用于抑制tie2激酶的方法
JP2012229273A (ja) ５−ｆｕおよび５−ｆｕプロドラッグと併用してｄｐｄ阻害物質を投与するための方法
CN113164415A (zh) 依拉司群和阿贝西利在患乳腺癌女性中的联合应用
JP6860949B2 (ja) 癌の処置方法
KR20210106483A (ko) Mdm2 억제제를 위한 확장된 저용량 요법
WO2013064692A1 (en) Triple combination for the treatment of cancer
TW202231283A (zh) 用於治療轉移性大腸直腸癌之經改良之基於氟尿嘧啶之多藥劑化學治療
US20110151020A1 (en) Active substance combination with gemcitabine for the treatment of epithelial cancer
EP2755662B1 (en) Combinations of ribavirin and gdc-0449 for the treatment of leukaemia
Nehra et al. Olutasidenib: A ray of hope in the treatment of acute myeloid leukaemia
SG11202112061RA (en) Bisfluoroalkyl-1,4-benzodiazepin one compounds for treating notch-activated breast cancer
CA3253688A1 (en) TREATMENT METHODS FOR SMALL CELL LUNG CANCER
CN114728003B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
Thomas et al. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer: GFPC 99-01 study (Groupe français de pneumo-cancérologie)
JP2022513320A (ja) Ｆｌｔ３が変異した血液のがんを処置する方法
Li et al. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer
FR2910813A1 (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
Adachi et al. Clinical Phase I Study of TAS102/Irinotecan/Bevacizumab Combination Therapy in Japanese Patients With Unresectable Metastatic Colorectal Cancer (mCRC)
HK40078096A (en) Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors
KR102356393B1 (ko) 두경부암의 치료 또는 예방에 사용하기 위한 pi3 키나제 억제제와 파클리탁셀의 조합물
CN121925259A (zh) 血液癌的新型联合疗法
HK40069821A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination